GlassScriptPhysician profile
Dmitry Finkelberg
NPI 1134326218
$5,615.84
in general payments reported to CMS, 2019-2025
21 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $572 · 2021: $865 · 2022: $1,240 · 2023: $1,551 · 2024: $814 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,562.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,599.11 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,530.37 | 2019-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $409.59 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $317.63 | 2020-2024 | Stelara, Simponi Aria, Simponi |
| Braintree Laboratories, INC. | $302.97 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $252.54 | 2021-2023 | Rebyota, Cimzia |
| Celgene Corporation | $202.04 | 2022-2024 | Zeposia |
| Pfizer INC. | $199.10 | 2019-2025 | |
| Genzyme Corporation | $162.65 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.54 | 2019-2023 | Entyvio |
| Daiichi Sankyo INC. | $104.85 | 2022-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $99.04 | 2020-2023 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $95.01 | 2022-2023 | Givlaari |
| Fujifilm Healthcare Americas Corporation | $52.09 | 2023 | Fujifilm |
| Allergan, INC. | $50.43 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $34.45 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.17 | 2024 | Cyltezo |
| Ardelyx, INC. | $19.13 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $17.56 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.79 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $6.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Finkelberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.